Zobrazeno 1 - 10
of 37
pro vyhledávání: '"for the Alzheimer's Disease Cooperative Study"'
Autor:
Aladdin H. Shadyab, Andrea Z. LaCroix, Genevieve Matthews, Daniel Bennett, Alexandre A. Shadyab, Donna Tan, Ronald G. Thomas, Jennifer Mason, Alex Lopez, Brianna Askew, Lia Donahue, Stephen Kaplita, Irfan A. Qureshi, Branko Huisa, Howard H. Feldman, for the Alzheimer's Disease Cooperative Study T2 Protect AD Study Group
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 8, Iss 1, Pp n/a-n/a (2022)
Abstract Introduction The reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much‐needed therapeutic progress. Methods T2 Protect AD (T2),
Externí odkaz:
https://doaj.org/article/3dbbcd093b374371bfd8f4807d5a6508
Autor:
Michelle M. Nuño, Daniel L. Gillen, Joshua D. Grill, for the Alzheimer’s Disease Cooperative Study
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-7 (2019)
Abstract Background Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose role includes assessing participant cognitive and functional performance. AD trials now investigate early stages of the dise
Externí odkaz:
https://doaj.org/article/4f9a50e6b8f74e5c9ab51d70d8746ad1
Autor:
Diane M. Jacobs, Ronald G. Thomas, David P. Salmon, Shelia Jin, Howard H. Feldman, Carl W. Cotman, Laura D. Baker, for the Alzheimer's Disease Cooperative Study EXERT Study Group, for the Alzheimer's Disease Neuroimaging Initiative
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)
Abstract Introduction Use of cognitive composites as primary outcome measures is increasingly common in clinical trials of preclinical and prodromal Alzheimer's disease (AD). Composite outcomes can decrease intra‐individual variability, resulting i
Externí odkaz:
https://doaj.org/article/58a88913ae004aad972c20c44181a15d
Autor:
Shadyab, Aladdin H, LaCroix, Andrea Z, Matthews, Genevieve, Bennett, Daniel, Shadyab, Alexandre A, Tan, Donna, Thomas, Ronald G, Mason, Jennifer, Lopez, Alex, Askew, Brianna, Donahue, Lia, Kaplita, Stephen, Qureshi, Irfan A, Huisa, Branko, Feldman, Howard H, Alzheimer's Disease Cooperative Study T2 Protect AD Study Group
Publikováno v:
Alzheimer's & dementia (New York, N. Y.), vol 8, iss 1
IntroductionThe reporting of approaches facilitating the most efficient and timely recruitment of Alzheimer's disease (AD) patients into pharmacologic trials is fundamental to much-needed therapeutic progress.MethodsT2 Protect AD (T2), a phase 2 rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::c314c1e2795ccf3a335fc28f600c93ad
https://escholarship.org/uc/item/2tz5x9hr
https://escholarship.org/uc/item/2tz5x9hr
Autor:
Stites, Shana D, Turner, R Scott, Gill, Jeanine, Gurian, Anna, Karlawish, Jason, Grill, Joshua D, Alzheimer’s Disease Cooperative Study
Publikováno v:
Clinical trials (London, England), vol 18, iss 2
BackgroundMissing data are a notable problem in Alzheimer's disease clinical trials. One cause of missing data is participant dropout. The Research Attitudes Questionnaire is a 7-item instrument that measures an individual's attitudes toward biomedic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::981be577194c03ff98d1f6fd0a173fe9
https://escholarship.org/uc/item/0ch947x6
https://escholarship.org/uc/item/0ch947x6
Autor:
Hakhu, Navneet R., Gillen, Daniel L., Grill, Joshua D., Alzheimer’s Disease Cooperative Study
Publikováno v:
Alzheimer Disease & Associated Disorders; Jul-Sep2022, Vol. 36 Issue 3, p192-199, 8p
Autor:
Jacobs, Diane M, Thomas, Ronald G, Salmon, David P, Jin, Shelia, Feldman, Howard H, Cotman, Carl W, Baker, Laura D, Alzheimer's Disease Cooperative Study EXERT Study Group, Alzheimer's Disease Neuroimaging Initiative
Publikováno v:
Alzheimer's & dementia (New York, N. Y.), vol 6, iss 1
IntroductionUse of cognitive composites as primary outcome measures is increasingly common in clinical trials of preclinical and prodromal Alzheimer's disease (AD). Composite outcomes can decrease intra-individual variability, resulting in improved s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::0a2f4993fed1ac8f69d9c28ac0077f73
https://escholarship.org/uc/item/858983cn
https://escholarship.org/uc/item/858983cn
Autor:
Schneider, Lon S, Thomas, Ronald G, Hendrix, Suzanne, Rissman, Robert A, Brewer, James B, Salmon, David P, Oltersdorf, Tilman, Okuda, Tomohiro, Feldman, Howard H, Alzheimer’s Disease Cooperative Study TCAD Study Group
Publikováno v:
JAMA neurology, vol 76, iss 11
ImportanceEdonerpic maleate (T-817MA) protects against Aβ40-induced neurotoxic effects and memory deficits, promotes neurite outgrowth, and preserves hippocampal synapses and spatial memory in tau transgenic mice. These effects may be mediated via s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::26fa3ccbc5a5725274250df1a1dd683f
https://escholarship.org/uc/item/99j1z337
https://escholarship.org/uc/item/99j1z337
Autor:
Relkin, Norman R, Thomas, Ronald G, Rissman, Robert A, Brewer, James B, Rafii, Michael S, van Dyck, Christopher H, Jack, Clifford R, Sano, Mary, Knopman, David S, Raman, Rema, Szabo, Paul, Gelmont, David M, Fritsch, Sandor, Aisen, Paul S, Alzheimer's Disease Cooperative Study
Publikováno v:
Neurology, vol 88, iss 18
ObjectiveWe tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia.MethodsIn a phase 3, double-blind, placebo-controlled trial, we randomly assigned 390 participants with mil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::21a383ae914247c5fc0754f458179f6f
https://escholarship.org/uc/item/65s6h93f
https://escholarship.org/uc/item/65s6h93f
Autor:
Turner, R Scott, Thomas, Ronald G, Craft, Suzanne, van Dyck, Christopher H, Mintzer, Jacobo, Reynolds, Brigid A, Brewer, James B, Rissman, Robert A, Raman, Rema, Aisen, Paul S, Alzheimer's Disease Cooperative Study
Publikováno v:
Neurology, vol 85, iss 16
ObjectiveA randomized, placebo-controlled, double-blind, multicenter 52-week phase 2 trial of resveratrol in individuals with mild to moderate Alzheimer disease (AD) examined its safety and tolerability and effects on biomarker (plasma Aβ40 and Aβ4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::25a438a322ba35e2682e96cbd730c34b
https://escholarship.org/uc/item/00p1c7db
https://escholarship.org/uc/item/00p1c7db